P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847120.16268.0f |
| _version_ | 1797287898043645952 |
|---|---|
| author | A. Yacoub U. Borate R. Rampal H. Ali E. Wang A. Gerds G. Hobbs M. Kremyanskaya E. Winton C. O’Connell S. Goel S. Oh G. Schiller A. Assad S. Erickson-Viitanen F. Zhou N. Daver |
| author_facet | A. Yacoub U. Borate R. Rampal H. Ali E. Wang A. Gerds G. Hobbs M. Kremyanskaya E. Winton C. O’Connell S. Goel S. Oh G. Schiller A. Assad S. Erickson-Viitanen F. Zhou N. Daver |
| author_sort | A. Yacoub |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:29Z |
| format | Article |
| id | doaj.art-5624e8a7b6a24ecd8a961b6f5c6dc8ef |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:29Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-5624e8a7b6a24ecd8a961b6f5c6dc8ef2024-03-02T03:51:49ZengWileyHemaSphere2572-92412022-06-01695395410.1097/01.HS9.0000847120.16268.0f202206003-00953P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDYA. Yacoub0U. Borate1R. Rampal2H. Ali3E. Wang4A. Gerds5G. Hobbs6M. Kremyanskaya7E. Winton8C. O’Connell9S. Goel10S. Oh11G. Schiller12A. Assad13S. Erickson-Viitanen14F. Zhou15N. Daver161 University of Kansas Cancer Center, Westwood2 Oregon Health & Science University, Portland3 Memorial Sloan Kettering Cancer Center, New York4 City of Hope National Medical Center, Duarte5 Roswell Park Comprehensive Cancer Center, Buffalo6 Cleveland Clinic, Cleveland7 Massachusetts General Hospital, Boston8 Icahn School of Medicine at Mount Sinai, New York9 Emory University, Atlanta10 University of Southern California, Los Angeles11 Montefiore Medical Center, Bronx12 Washington University School of Medicine, St. Louis13 David Geffen School of Medicine, University of California Los Angeles, Los Angeles14 Incyte Corporation, Wilmington14 Incyte Corporation, Wilmington14 Incyte Corporation, Wilmington15 University of Texas MD Anderson Cancer Center, Houston, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847120.16268.0f |
| spellingShingle | A. Yacoub U. Borate R. Rampal H. Ali E. Wang A. Gerds G. Hobbs M. Kremyanskaya E. Winton C. O’Connell S. Goel S. Oh G. Schiller A. Assad S. Erickson-Viitanen F. Zhou N. Daver P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY HemaSphere |
| title | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_full | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_fullStr | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_full_unstemmed | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_short | P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY |
| title_sort | p1063 efficacy and safety of parsaclisib ruxolitinib combination therapy in myelofibrosis patients with low vs higher baseline platelet count a subgroup analysis of data from a phase 2 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000847120.16268.0f |
| work_keys_str_mv | AT ayacoub p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT uborate p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT rrampal p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT hali p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ewang p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT agerds p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ghobbs p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT mkremyanskaya p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ewinton p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT coconnell p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT sgoel p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT soh p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT gschiller p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT aassad p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT sericksonviitanen p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT fzhou p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study AT ndaver p1063efficacyandsafetyofparsaclisibruxolitinibcombinationtherapyinmyelofibrosispatientswithlowvshigherbaselineplateletcountasubgroupanalysisofdatafromaphase2study |